DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Priscoline (Tolazoline Hydrochloride) - Description and Clinical Pharmacology


Priscoline hydrochloride injection®


      Priscoline® hydrochloride

      tolazoline hydrochloride injection, USP


      Rx only

      Prescribing Information


Priscoline hydrochloride, tolazoline hydrochloride injection, USP, is a peripheral vasodilator available in ampuls for intravenous administration. Each milliliter of sterile, aqueous solution contains tolazoline hydrochloride USP, 25 mg; tartaric acid ACS, 6.5 mg; and hydrous sodium citrate USP, 6.5 mg. Tolazoline hydrochloride is 4,5-dihydro-2-(phenylmethyl)-
1 H -imidazole monohydrochloride, and its structural formula is

Tolazoline hydrochloride USP is a white to off-white crystalline powder. Its solutions are slightly acid to litmus. It is freely soluble in water and in alcohol. Its molecular weight is 196.68.


Priscoline is a direct peripheral vasodilator with moderate competitive alpha-adrenergic blocking activity. It decreases peripheral resistance and increases venous capacitance. It has the following additional actions: (1) sympathomimetic, including cardiac stimulation; (2) parasympathomimetic, including gastrointestinal tract stimulation that is blocked by atropine; and (3) histamine-like, including stimulation of gastric secretion and peripheral vasodilatation. Priscoline given intravenously produces vasodilatation, primarily due to a direct effect on vascular smooth muscle, and cardiac stimulation; the blood pressure response depends on the relative contributions of the two effects. Priscoline usually reduces pulmonary arterial pressure and vascular resistance.

In neonates the half-life of Priscoline ranges from 3 to 10 hours.

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017